Immunovant, Inc. (IMVT)
NASDAQ: IMVT · Real-Time Price · USD
26.99
-1.63 (-5.70%)
At close: Apr 28, 2026, 4:00 PM EDT
27.39
+0.40 (1.48%)
After-hours: Apr 28, 2026, 6:49 PM EDT
Company Description
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases.
It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren’s disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease.
The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Immunovant, Inc.
| Country | United States |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 362 |
| CEO | Eric Venker |
Contact Details
Address: 1000 Park Forty Plaza, Suite 210 Durham, North Carolina 27713 United States | |
| Phone | (917) 410-3120 |
| Website | immunovant.com |
Stock Details
| Ticker Symbol | IMVT |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001764013 |
| CUSIP Number | 45258J102 |
| ISIN Number | US45258J1025 |
| Employer ID | 83-2771572 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Eric Venker M.D., Pharm.D. | Chief Executive Officer and Director |
| Dr. Frank M. Torti M.B.A., M.D. | Executive Chairperson of the Board |
| Melanie Gloria B.S.N. | Chief Operating Officer |
| Christopher A. Van Tuyl Esq., J.D. | Chief Legal Officer and Corporate Secretary |
| Tiago M. Girao CPA | Chief Financial Officer |
| Dr. Jay S. Stout M.S., Ph.D. | Chief Technology Officer |
| Christine Blodgett | Senior Vice President of Human Resources |
| Andy Deig M.B.A. | Senior Vice President of Strategic Finance |
| Julie Kirschling | Senior Vice President of Program and Alliance Management |
| Becky Merlina | Senior Vice President and Global Head of Quality |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 10, 2026 | 144 | Filing |
| Feb 6, 2026 | 10-Q | Quarterly Report |
| Feb 6, 2026 | 8-K | Current Report |
| Dec 12, 2025 | SCHEDULE 13D/A | Filing |
| Dec 12, 2025 | 8-K | Current Report |
| Dec 12, 2025 | 424B5 | Filing |
| Dec 11, 2025 | 8-K | Current Report |
| Dec 11, 2025 | FWP | Free Writing Prospectus |
| Dec 1, 2025 | 144 | Filing |
| Dec 1, 2025 | 144 | Filing |